Knopp Neurosciences is a drug discovery and development company focused on delivering breakthrough treatments in neurological disorders through innovation, experience and partnership. Knopp’s lead compound, KNS-760704, is currently in clinical development for amyotrophic lateral sclerosis, with additional indications under investigation.
PARTNERSHIP
Knopp has aligned with world leaders in the fields supporting drug discovery and development. We leverage their talents to accelerate and advance the diagnosis and treatment of neurological disorders including ALS. Scientists, physicians and other professionals from these firms act as key players on the Knopp team.
INNOVATION
Knopp employs innovative approaches to persistent problems in drug discovery and development. Our scientists and discovery partners drive advances in proteomics, electrophysiology, molecular biology, and process chemistry. Our clinical leaders and development partners drive advances in safety and medical outcomes.
EXPERIENCE
The Knopp team combines executive experience, regulatory know-how, and entrepreneurial agility. Former senior executives from Bristol-Myers Squibb, emerging biotech companies, and leading Contract Research Organizations are joined by veterans of technology investing and venture creation.
Latest News
Knopp Neurosciences Initiates Phase 2 Study of KNS-760704 in Amyotrophic Lateral Sclerosis
04/08/2008PITTSBURGH, Pa., April 7, 2008--Knopp Neurosciences Inc. ("Knopp") said it initiated the first Phase...
KNS-760704 in ALS Featured in BioCentury
04/03/2008SAN CARLOS, Ca., March 31, 2008--"Knopp Neurosciences Inc. sees therapeutic potential in what was pr...